GPT Healthcare growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr2 yr
Revenue+16.1%+8.7%
EBITDA+1.0%−2.1%
Net Income−15.4%−6.0%
EPS (adj.)−15.4%−6.0%
Total Assets+21.0%+16.0%
Total Equity+8.7%+11.1%
Free Cash Flow+125.3%−10.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

GPTHEALTH₹134.48

GPT Healthcare Limited

· Pharma & Health
₹ CrorePeersGKSLSHALBYINDRAMEDCOLOTUSEYEARTEMISMEDDRAGARWQKMCSHILKOVAIMcap ₹1,103 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
2Y
CAGR
Revenue+16.1+8.7
EBITDA+1.0-2.1
Net Income-15.4-6.0
EPS (adj.)-15.4-6.0
Total Assets+21.0+16.0
Total Equity+8.7+11.1
Free Cash Flow+125.3-10.8
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.